Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
Adult
Aged
Artifacts
Biomarkers
/ metabolism
Breast
/ diagnostic imaging
Breast Neoplasms
/ diagnostic imaging
Chemotherapy, Adjuvant
Clinical Trials as Topic
Contrast Media
Diffusion Magnetic Resonance Imaging
Female
Humans
Image Interpretation, Computer-Assisted
/ methods
Middle Aged
Neoadjuvant Therapy
Neoplasms
/ diagnostic imaging
Observer Variation
Prospective Studies
Quality Assurance, Health Care
Quality Control
Receptor, ErbB-2
/ metabolism
Reproducibility of Results
Signal-To-Noise Ratio
breast MRI
breast cancer
diffusion
reproducibility
treatment response
Journal
Journal of magnetic resonance imaging : JMRI
ISSN: 1522-2586
Titre abrégé: J Magn Reson Imaging
Pays: United States
ID NLM: 9105850
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
07
03
2018
revised:
20
09
2018
accepted:
22
09
2018
pubmed:
24
10
2018
medline:
7
10
2020
entrez:
24
10
2018
Statut:
ppublish
Résumé
Quantitative diffusion-weighted imaging (DWI) MRI is a promising technique for cancer characterization and treatment monitoring. Knowledge of the reproducibility of DWI metrics in breast tumors is necessary to apply DWI as a clinical biomarker. To evaluate the repeatability and reproducibility of breast tumor apparent diffusion coefficient (ADC) in a multi-institution clinical trial setting, using standardized DWI protocols and quality assurance (QA) procedures. Prospective. In all, 89 women from nine institutions undergoing neoadjuvant chemotherapy for invasive breast cancer. DWI was acquired before and after patient repositioning using a four b-value, single-shot echo-planar sequence at 1.5T or 3.0T. A QA procedure by trained operators assessed artifacts, fat suppression, and signal-to-noise ratio, and determine study analyzability. Mean tumor ADC was measured via manual segmentation of the multislice tumor region referencing DWI and contrast-enhanced images. Twenty cases were evaluated multiple times to assess intra- and interoperator variability. Segmentation similarity was assessed via the Sørenson-Dice similarity coefficient. Repeatability and reproducibility were evaluated using within-subject coefficient of variation (wCV), intraclass correlation coefficient (ICC), agreement index (AI), and repeatability coefficient (RC). Correlations were measured by Pearson's correlation coefficients. In all, 71 cases (80%) passed QA evaluation: 44 at 1.5T, 27 at 3.0T; 60 pretreatment, 11 after 3 weeks of taxane-based treatment. ADC repeatability was excellent: wCV = 4.8% (95% confidence interval [CI] 4.0, 5.7%), ICC = 0.97 (95% CI 0.95, 0.98), AI = 0.83 (95% CI 0.76, 0.87), and RC = 0.16 * 10 Breast tumor ADC can be measured with excellent repeatability and reproducibility in a multi-institution setting using a standardized protocol and QA procedure. Improvements to DWI image quality could reduce loss of data in clinical trials. 2 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;49:1617-1628.
Sections du résumé
BACKGROUND
Quantitative diffusion-weighted imaging (DWI) MRI is a promising technique for cancer characterization and treatment monitoring. Knowledge of the reproducibility of DWI metrics in breast tumors is necessary to apply DWI as a clinical biomarker.
PURPOSE
To evaluate the repeatability and reproducibility of breast tumor apparent diffusion coefficient (ADC) in a multi-institution clinical trial setting, using standardized DWI protocols and quality assurance (QA) procedures.
STUDY TYPE
Prospective.
SUBJECTS
In all, 89 women from nine institutions undergoing neoadjuvant chemotherapy for invasive breast cancer.
FIELD STRENGTH/SEQUENCE
DWI was acquired before and after patient repositioning using a four b-value, single-shot echo-planar sequence at 1.5T or 3.0T.
ASSESSMENT
A QA procedure by trained operators assessed artifacts, fat suppression, and signal-to-noise ratio, and determine study analyzability. Mean tumor ADC was measured via manual segmentation of the multislice tumor region referencing DWI and contrast-enhanced images. Twenty cases were evaluated multiple times to assess intra- and interoperator variability. Segmentation similarity was assessed via the Sørenson-Dice similarity coefficient.
STATISTICAL TESTS
Repeatability and reproducibility were evaluated using within-subject coefficient of variation (wCV), intraclass correlation coefficient (ICC), agreement index (AI), and repeatability coefficient (RC). Correlations were measured by Pearson's correlation coefficients.
RESULTS
In all, 71 cases (80%) passed QA evaluation: 44 at 1.5T, 27 at 3.0T; 60 pretreatment, 11 after 3 weeks of taxane-based treatment. ADC repeatability was excellent: wCV = 4.8% (95% confidence interval [CI] 4.0, 5.7%), ICC = 0.97 (95% CI 0.95, 0.98), AI = 0.83 (95% CI 0.76, 0.87), and RC = 0.16 * 10
DATA CONCLUSION
Breast tumor ADC can be measured with excellent repeatability and reproducibility in a multi-institution setting using a standardized protocol and QA procedure. Improvements to DWI image quality could reduce loss of data in clinical trials.
LEVEL OF EVIDENCE
2 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;49:1617-1628.
Identifiants
pubmed: 30350329
doi: 10.1002/jmri.26539
pmc: PMC6524146
mid: NIHMS1027800
doi:
Substances chimiques
Biomarkers
0
Contrast Media
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1617-1628Subventions
Organisme : NCI NIH HHS
ID : U01 CA225427
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA190299
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB015894
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA080098
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA140204
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA166104
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA189828
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA079778
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA151235
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180794
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA132870
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233160
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180820
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA151326
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA180803
Pays : United States
Informations de copyright
© 2018 International Society for Magnetic Resonance in Medicine.
Références
J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36
pubmed: 11121466
Br J Cancer. 2006 Feb 13;94(3):427-35
pubmed: 16465174
J Biopharm Stat. 2007;17(4):529-69
pubmed: 17613641
NMR Biomed. 2009 Jan;22(1):104-13
pubmed: 18384182
Clin Pharmacol Ther. 2009 Jul;86(1):97-100
pubmed: 19440188
Eur Radiol. 2010 Feb;20(2):303-8
pubmed: 19760422
Transl Oncol. 2009 Dec;2(4):231-5
pubmed: 19956383
Magn Reson Imaging. 2010 Apr;28(3):320-8
pubmed: 20061111
Acta Oncol. 2010 Apr;49(3):354-60
pubmed: 20397769
Radiol Med. 2011 Apr;116(3):466-76
pubmed: 21225368
Med Oncol. 2012 Jun;29(2):425-31
pubmed: 21286861
J Magn Reson Imaging. 2011 Oct;34(4):983-7
pubmed: 21928310
Eur Radiol. 2012 Jul;22(7):1512-8
pubmed: 22367471
Radiology. 2012 Jun;263(3):663-72
pubmed: 22623692
J Magn Reson Imaging. 2013 May;37(5):1238-46
pubmed: 23023785
Eur Radiol. 2013 Sep;23(9):2420-31
pubmed: 23652844
J Biopharm Stat. 2014;24(4):893-907
pubmed: 24697741
Transl Oncol. 2014 Feb 01;7(1):94-100
pubmed: 24772212
Transl Oncol. 2014 Feb 01;7(1):130-7
pubmed: 24772216
J Magn Reson Imaging. 2015 Sep;42(3):779-87
pubmed: 25580585
PLoS One. 2015 Mar 27;10(3):e0122151
pubmed: 25816249
Clin Breast Cancer. 2015 Oct;15(5):370-80
pubmed: 25891905
Eur J Radiol. 2015 Sep;84(9):1729-36
pubmed: 26078100
Eur Radiol. 2016 Jul;26(7):2291-6
pubmed: 26443604
J Korean Med Sci. 2015 Nov;30(11):1689-97
pubmed: 26539016
Radiology. 2016 Apr;279(1):44-55
pubmed: 26624971
NMR Biomed. 2016 Oct;29(10):1445-53
pubmed: 27553252
Eur Radiol. 2017 May;27(5):1883-1892
pubmed: 27578047
J Magn Reson Imaging. 2017 Feb;45(2):337-355
pubmed: 27690173
J Magn Reson Imaging. 2018 Feb;47(2):401-409
pubmed: 28640531
J Magn Reson Imaging. 2018 Mar 23;:
pubmed: 29570895
Radiology. 2018 Dec;289(3):618-627
pubmed: 30179110
Biometrics. 1996 Dec;52(4):1195-203
pubmed: 8962450